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Parkinson’s disease (PD) is a devastating age related neurodegenerative disease that
is believed to have a lengthy prodromal state. It is critical to find methods to harness
compensatory recovery processes in order to slow or prevent the eventual progression of
clinical symptoms. The current perspective paper argues that immune system signaling
molecules represent such a promising therapeutic approach. Two cytokines of interest
are granulocyte macrophage-colony stimulating factor (GM-CSF) and erythropoietin
(EPO). These hematopoietic cytokines have been protective in models of stroke, neuronal
injury, and more recently PD. It is our belief that these trophic cytokines can be used
not only for cell protection but also regeneration. However, success is likely dependent
on early intervention. This paper will outline our perspective on the development of
novel trophic recovery treatments for PD. In particular, we present new data from our
lab suggesting that EPO and GM-CSF can foster neural re-innervation in a “mild” or
partial lesion PD model that could be envisioned as reflecting the early stages of the
disease.
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Parkinson’s Disease: Animal Model of Early Stages
Parkinson’s disease (PD) is characterized by a loss of dopamine (DA) neurons within
the nigrostriatal pathway and the presence of Lewy body pathological protein aggregates
(Farrer et al., 2001; Sherer et al., 2001). Clinically, PD is diagnosed based on tremors
within distal limbs, muscle rigidity, and bradykinesia. By the time patients present with
these motor symptoms, there has already been significant degeneration of DA neurons,
with up to an 80% loss of striatal DA innervation (Bezard et al., 2001). There are also
extensive non-motor symptoms, which present long before the cardinal motor symptoms
(McDonald et al., 2003).
Current PD treatments only manage symptom severity and are not able to reverse or even
appreciably slow the neurodegenerative processes. Thus, it is of interest to investigate potential
treatments that could stabilize these surviving neurons and possibly induce some degree
of neuronal recovery. It might be advantageous to target processes linked to the early
or prodromal stages of PD, as neuronal plasticity would likely be more amenable to
modulation at such times. However, models of early stage PD are less common and not
as well understood as the late stage typically used. The neurotoxin, 6-hydroxydopamine
(6-OHDA), is routinely used to induce PD-like pathology, inducing a loss of substantia
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nigra pars compacta (SNc) DA neurons and downstream striatal
terminals (Alvarez-Fischer et al., 2008). 6-OHDA infused directly
into the SNc rapidly produces a robust degeneration of SNc
DA neurons, coupled with striatal DA depletion within 48–72 h
(Blandini et al., 2008; Thiele et al., 2012). However, this
method has the obvious caveat of not reflecting the chronic
slow course of degeneration. A more progressive lesion has
been observed with lower doses of 6-OHDA infused into
the striatum rather than SNc. Indeed, intra-striatal 6-OHDA
administration induced a lesion, which gradually increased
in size over several weeks (Sauer and Oertel, 1994) and
more closely mimicked the progression from early to later
stages of PD.
Novel Treatment Strategies
One exciting new avenue for treating PD involves the use
of trophic factors to stabilize neuronal viability and even
promote some degree of recovery. In fact, recent studies
have revealed a reduction of brain derived neurotrophic
factor (BDNF) within the SNc of PD patients (Mogi
et al., 1999; Salehi and Mashayekhi, 2009). Accordingly,
BDNF can promote the survival and differentiation of
mesencephalic DA neurons, as well as protect against the
DA toxicants, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and 6-OHDA (Murer et al., 2001). Likewise, glial
derived neurotrophic factor (GDNF), has also emerged as
a potential candidate for neuroprotection in PD patients,
based on success in various animal models (Fox et al., 2001;
Ai et al., 2003). However, the improvements observed
in clinical trials were restricted to the immediate area
surrounding the site of infusion (Gill et al., 2003) and
a randomized placebo-controlled study was unsuccessful
at replicating these beneficial effects (Lang et al., 2006).
Moreover, BDNF and GDNF do not readily cross the
blood brain barrier (BBB) and have numerous side effects
(Pezet and McMahon, 2006; Pilakka-Kanthikeel et al.,
2013).
Finding well-tolerated factors with trophic properties, which
cross the BBB represents a considerable challenge. Two
cytokines that may hold potential therapeutic significance are the
hematopoietic cytokines, erythropoietin (EPO) and granulocyte
macrophage-colony stimulating factor (GM-CSF). Indeed, GM-
CSF had protective effects in models of Alzheimer’s disease
(Boyd et al., 2010), and in MPTP and paraquat models of
PD (Kim et al., 2009; Mangano et al., 2011). Moreover, GM-
CSF administration induced spontaneous axonal regeneration
and functional recovery from traumatic spinal cord injury (Ha
et al., 2005; Bouhy et al., 2006) and reduced infarct volume
following ischemia (Nakagawa et al., 2006; Schäbitz et al.,
2008). Similarly, EPO has been investigated extensively for
use in stroke, traumatic head injury and more recently, in
toxin based animal models of PD (Sargin et al., 2010; Merelli
et al., 2013; Bond and Rex, 2014). EPO was also shown to
protect hippocampal neurons from stressor-induced apoptosis,
and increased adult hippocampal neurogenesis (Merelli et al.,
2015).
GM-CSF and EPO have well-documented trophic
actions in the periphery and can infiltrate and accumulate
within the brain (Enzler and Dranoff, 2003). Receptors
for GM-CSF and EPO have been found on mature DA
neurons and neural progenitor cells, suggesting that
they might influence adult neuronal functioning, as well
as stimulate maturation (Kim et al., 2004; Ha et al.,
2005).
The peripheral function of GM-CSF is to promote the
differentiation and maturation of innate immune cells, and it is
routinely administered to cancer patients to modify neutrophil
production (Dale et al., 1998). Similarly, EPO has potent
mitogenic effects on immune cells, as well as red blood cells and
is routinely prescribed for anemia and in the context of certain
cancer treatments (Debeljak et al., 2014). Thus, both also have
well established clinical track records.
GM-CSF and EPO Promote Striatal
Re-Innervation
It is thought that a slow progressive ‘‘wave’’ of neurodegeneration
occurs over many years before a critical threshold of neuronal
loss is reached and clinical PD pathology is manifested.
Accordingly, it is of interest to study the effects of potential
treatments while the disease is still in an early or possibly
even a prodromal stage. In the present paper, it was of
interest to assess whether EPO or GM-CSF treatment could
influence striatal innervation following the establishment
of a partial or ‘‘mild’’ lesion that might be analogous to
the early onset of the disease. To this end, male Sprague
Dawley rats received a single intra-striatum (1.0 mm anterior,
3.0 mm lateral, 5.0 mm ventral relative to bregma) infusion
of 6-OHDA (20 µg). Animals were then randomly divided
into three groups (n = 7): Saline, EPO, and GM-CSF. On
post-6-OHDA infusion Days 13 and 28, the animals received
an intraperitoneal injection of either saline, recombinant
human EPO solution (rhEPO; 50 µg/kg) or recombinant
rat granulocyte-macrophage colony-stimulating factor
solution (rat GM-CSF; 10 µg/kg). Animals were sacrificed
on Day 30.
As shown in Figure 1, we did indeed find that a modest
[∼10% of striatal area, as determined using tyrosine hydroxylase
(TH) staining] lesion was induced in rats following intra-striatal
infusion of a single moderate dose of 6-OHDA. However, no
significant neuronal loss was evident within the SNc using this
relatively mild paradigm, although it is possible that some of
these SNc neurons would eventually die if we explored longer
time intervals. Indeed, many surviving neurons had irregular
shaped soma (Figure 2).
Importantly, the two EPO and GM-CSF injections that were
given after the presumed establishment of the lesion (i.e., onDays
13 and 28 following 6-OHDA) provoked a significant recovery
(presumed re-innervation) of striatal terminals. The statistical
analysis revealed a significant treatment effect, F(2,15) = 10.7,
P < 0.01, with regards to striatal lesion size (Figure 1), such that
the cytokines prevented the striatal lesion by Day 30 following
6-OHDA.
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FIGURE 1 | Thirty days after the intra-striatal infusion of 6-OHDA,
saline treated animals (graph—white bars; A) had a modest but
statistically significant loss of TH+ striatal fibers. The GM-CSF
(graph—black bars; B) and EPO (graph—black bars; C) treated animals
displayed no visible lesion at the 30-day sacrifice time. Data is expressed
as mean ± 1 SEM, *p < 0.01.
FIGURE 2 | Neurons were counted in an unbiased manner using MBF
Stereo investigator optical fractionator probe. There were no significant
differences between treatment groups (left graph). Photomicrographs are
representative of animals treated with (A) Saline; (B) GM-CSF; or (C) EPO in
conjunction with 6-OHDA infusion. The saline (but not GM-CSF or EPO) treated
rats that received 6-OHDA displayed TH+ neurons with an abnormal shaped
nucleus, with a reduction of projections. Images were taken at 40 ×
magnification.
The present findings are consistent with our own previous
data and those of others showing beneficial effects of GM-
CSF (Mangano et al., 2011; Kosloski et al., 2013) and EPO
(Xue et al., 2007; Dhanushkodi et al., 2013; Qi et al., 2014)
in toxicant animal models. However, since GM-CSF or EPO
were administered after lesion establishment, the effects of the
cytokine treatments in the current study would be expected
to reflect some degree of recovery involving DA fiber re-
growth rather than the prevention of fiber loss in the first
place. This is a particularly novel finding given that the
majority of studies typically focus on neuroprotective effects,
rather than addressing the more clinically relevant issue
of promoting recovery following some degree of neuronal
damage.
Impact and Future Directions
It is important to underscore that the 6-OHDA paradigm
presently used provoked a very modest loss of striatal terminals
and future studies are required to ascertain whether GM-CSF
and EPO might also have reparative properties in PD models
with more significantly sized lesions. Nonetheless, GM-CSF
and EPO may be ideal trophic treatment candidates based
on their biological profiles, preclinical data and track record
of clinical applicability. Mechanistically, these cytokines are
potent inducers of BDNF and GDNF (Bouhy et al., 2006;
Mengozzi et al., 2012), which we posit to be fundamental
for their beneficial neural consequences. Targeting trophic
processes to boost plasticity may be a critically important shift
in treatment modalities away from failed attempts to translate
neuroprotective approaches to the clinic; this strategy would also
work well in tandem with recent efforts to identify biomarkers of
disease state.
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